LLY vs ABT
By Alex · Tickerpine
Eli Lilly and Company vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ABT |
|---|---|---|
| Price | $1,443.50 | $108.52 |
| Market cap | $1.29T | $187.95B |
| P/E ratio | 46.9 | 40.5 |
| ROE | 86.02% | 9.14% |
| Profit margin | 31.90% | 9.75% |
| Revenue growth | 38.60% | 14.50% |
| Dividend yield | 0.48% | 2.32% |
| Beta | 0.39 | 0.54 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ABT in plain English
- LLY is the bigger company — about 6.8× the market cap of ABT.
- ABT is cheaper on earnings (P/E 40.5 vs 46.9).
- LLY earns a higher return on equity (86% vs 9%).
- LLY is growing revenue faster (39% vs 14%).
- ABT has the higher dividend yield (2.32% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.